Investigation Report on China Trastuzumab Market 2009-2018

The report “Investigation Report on China Trastuzumab Market, 2009-2018″ by Research in China is now available at chinamarketresearchreports.com. Contact sales@chinamarketresearchreports.com with Investigation Report on China Trastuzumab Market, 2009-2018 in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Trastuzumab Market, 2009-2018”On chinamarketresearchreports.com. Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers. Trastuzumab has a major impact in the treatment of HER2positive metastatic breast cancers.

In China, less than 10% of women can get mammary diseases inspection every year for the limitation of medical conditions and lack of knowledge. Therefore, only 20% of breast cancers is detected at an early stage in China while 80% is detected at an early stage in the U.S.A.

Inquire for discount @ http://www.chinamarketresearchreports.com/contacts/inquiry.php?name=114713 .

The incidence of breast cancers ranks the first in malignant tumors. According to incomplete statistics, the incidence number of breast cancers exceeds 200,000 every year in China. By the end of 2013, the number of living breast cancer patients exceeded 500,000, above 1/3 of which were metastatic breast cancers. The incidence and mortality rates of breast cancers differ from urban to rural areas in China. In recent 10 years, the incidence of breast cancers in cities obviously increases but the mortality rate remains stable. However, the incidence and mortality rates of breast cancers in rural areas present obvious uprising trend. The number of breast cancer patients in cities is increasing, especially in young women groups. It is mainly caused by the change of lifestyle and diet habits and the incidence growth of other mammary diseases like fibroma. Take Fujian as an instance, from 1970s to the early 21 century, the mortality rate of breast cancers in Fujian presents an upward trend. The mortality rates in 19731975, 19901992 and 20042005 are separately 31.6/million, 34.2/million and 44.6/million. In 2011, the mortality rate of women breast cancer patients was 70.7/million in Fujian. Obviously, the mortality rate doubled during 20052011.

Complete report is available @ http://www.chinamarketresearchreports.com/114713.html . Read more on “Investigation Report on China Trastuzumab Market, 2009-2018” report below.

In China sample hospital market, the market share of trastuzumab is completely taken by Shanghai Roche and GENENTECH. During 20052013, the CAGR of market size of trastuzumab in sample hospitals exceeded 60%. The unit retail price maintains CNY 20,000 (USD 3,300) or more.

The patent of trastuzumab will expire in 2014. The huge profit margin and market potential attract many generic drug manufacturers. CRI sees many generic drugs will enter global market after 2015. According to CRI's investigation, many generic drug companies add trastuzumab to the R&D list, some of which has certain achievements.

Through this report, the readers can acquire the following information:

·         Market Share of Major Trastuzumab Manufacturers in Sample Hospitals in China

·         Sales price of Trastuzumab in Hospital Market in China

·         Major Trastuzumab enterprises in China

·         Market share of Trastuzumab by dosage form in hospital market in China

·         Incidence of breast cancers in China

·         Progress of trastuzumab generic drugs

·         Prospect of China trastuzumab market

The following enterprises and people are recommended to purchase this report:

·         Trastuzumab API and finished product manufacturers

·         Medical Institutions

·         Investors/research agencies focusing on trastuzumab market

Table of Contents

1 Relevant Concepts of Trastuzumab
1.1 Indication
1.2 Sales Status on the Global Market

2 Market Overview of Trastuzumab in China, 2009-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Trastuzumab in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Trastuzumab Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Trastuzumab by Dosage Form in China , 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form

6 Reference Price of Trastuzumab in Hospital Market in China, 2013
6.1 Trastuzumab Produced by Shanghai Roche (Brand Name: Herceptin)
6.2 Trastuzumab Produced by GENENTECH (Brand Name: Herceptin)

7 Analysis on Major Trastuzumab Manufacturers in China, 2009-2013
7.1 Shanghai Roche Pharmaceuticals Ltd.
7.2 GENENTECH (Subsidiary of Roche)

8 Prospect of China Trastuzumab Market, 2014-2018
8.1 Forecast on Incidence of Mammary Cancer
8.2 Forecast on Market Size
8.3 Forecast on Competition Pattern

For further information on “Investigation Report on China Trastuzumab Market, 2009-2018” report OR for any other business research / market intelligence need on the ‘Life Sciences’ market (http://www.chinamarketresearchreports.com/cat/life-sciences.html .), contact sales@chinamarketresearchreports.com / Call +1 888 391 5441.